Skip to main
IMTX

Immatics NV (IMTX) Stock Forecast & Price Target

Immatics NV (IMTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immatics NV's robust pipeline, particularly with the anzu-cel asset, presents a compelling opportunity in the oncology market, bolstered by the ongoing Phase 3 SUPRAME study, which aims to demonstrate improved progression-free survival (PFS) over control. The company's impressive manufacturing success rate of 98% and shortened turnaround times further enhance its operational efficiency, essential for meeting high unmet medical needs in the second-line metastatic cancer segment. Additionally, the granting of Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA signifies a favorable regulatory pathway, reinforcing the potential for significant market success in this $2 billion opportunity within the U.S. marketplace.

Bears say

Immatics NV faces a challenging outlook due to underwhelming clinical results, specifically with Brenetafusp data showing only an 11% overall response rate and a 56% disease control rate in advanced melanoma patients, which may lead to downward revisions in risk-adjusted projections. Additionally, the company is exposed to multiple risks, including potential R&D and regulatory setbacks, competition, lower than expected product sales, and dilutive financing, which could further negatively impact financial performance. In a downside scenario, if critical endpoints are not met and pipeline programs do not yield value, the company could face a valuation as low as $3 per share within the next year.

Immatics NV (IMTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immatics NV (IMTX) Forecast

Analysts have given Immatics NV (IMTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Immatics NV (IMTX) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immatics NV (IMTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.